Explore

Trendline Trendline
Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations
Trendline Trendline
Replimune Group Faces Fraud Investigation by Schall Law Firm

Replimune Group Faces Fraud Investigation by Schall Law Firm

Replimune Group Faces Fraud Investigation by Schall Law Firm
Trendline Trendline
Schall Law Firm Investigates Entrada Therapeutics for Potential Securities Violations

Schall Law Firm Investigates Entrada Therapeutics for Potential Securities Violations

Schall Law Firm Investigates Entrada Therapeutics for Potential Securities Violations
Trendline Trendline
Schall Law Firm Investigates Entrada Therapeutics for Potential Securities Fraud Impacting Investors

Schall Law Firm Investigates Entrada Therapeutics for Potential Securities Fraud Impacting Investors

Schall Law Firm Investigates Entrada Therapeutics for Potential Securities Fraud Impacting Investors
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Reuters Reuters
Regeneron drops after skin cancer treatment fails late-stage trial

Regeneron drops after skin cancer treatment fails late-stage trial

By Christy Santhosh May 18 (Reuters) - Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in a late-stage trial for patients with a type of skin cancer.
Trendline Trendline
FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements
Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026

Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026

Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Trendline Trendline
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments
Trendline Trendline
NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements
Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrower Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrower Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrower Loss in Q1 2026 Amid Clinical Developments